Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.57 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.43 |
| ▸ | GNPAT | O15228 | 1/20 | 0.40 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27411240 | 1.00 | GLP1R (0.57) | GLP1RNOD1FOLH1GNPATGLO1 | |
| SCHEMBL18560335 | 1.00 | GLP1R (0.57) | GLP1RNOD1FOLH1GNPATGLO1 | |
| SCHEMBL12673653 | 1.00 | GLP1R (0.57) | GLP1RNOD1FOLH1GNPATGLO1 | |
| SCHEMBL24899341 | 1.00 | GLP1R (0.57) | GLP1RNOD1FOLH1GNPATGLO1 | |
| SCHEMBL2177917 | 1.00 | GLP1R (0.57) | GLP1RNOD1FOLH1GNPATGLO1 | |
| SCHEMBL24390490 | 1.00 | GLP1R (0.57) | GLP1RNOD1FOLH1GNPATGLO1 | |
| SCHEMBL27407839 | 1.00 | GLP1R (0.57) | GLP1RNOD1FOLH1GNPATGLO1 | |
| SCHEMBL27409367 | 1.00 | GLP1R (0.57) | GLP1RNOD1FOLH1GNPATGLO1 | |
| SCHEMBL27408102 | 0.98 | GLP1R (0.58) | GLP1RNOD1FOLH1GLO1EPHX2 | |
| SCHEMBL23733386 | 0.98 | GLP1R (0.58) | GLP1RNOD1FOLH1GLO1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209028-A1 | CNP COMPOUNDS | NOVO NORDISK A/S (DK) | 2024-06-27 | — | — | US | disclosed |
| WO-2024094747-A1 | CNP COMPOUNDS | NOVO NORDISK A/S (DK) | 2024-05-10 | — | — | WO | disclosed |
| EP-4177263-A1 | NOVEL POLYPEPTIDE AND THERAPEUTIC USE THEREOF | Vitalixir (Beijing) Co., Ltd (CN) | 2023-05-10 | — | — | EP | disclosed |
| US-11130794-B2 | Bifunctional compounds | NOVO NORDISK A/S (DK) | 2021-09-28 | — | — | US | disclosed |
| US-20200407409-A1 | EGF(A) ANALOGUES WITH FATTY ACID SUBSTITUENTS | CHEN JIANHE (CN) | 2020-12-31 | — | — | US | disclosed |
| US-10822385-B2 | EGF(A) analogues with fatty acid substituents | NOVO NORDISK A/S (DK) | 2020-11-03 | — | — | US | disclosed |
| US-20200231645-A1 | Bifunctional compounds | NOVO NORDISK A/S (DK) | 2020-07-23 | — | — | US | disclosed |
| US-10588936-B2 | Modulators of complement activity | RA PHARMACEUTICALS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190307835-A1 | MODULATORS OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2019-10-10 | — | — | US | disclosed |
| US-20190016768-A1 | EGF(A) ANALOGUES WITH FATTY ACID SUBSTITUENTS | NOVO NORDISK A/S (DK) | 2019-01-17 | — | — | US | disclosed |
| US-20170137468-A1 | MODULATION OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2017-05-18 | — | — | US | disclosed |
| EP-2513141-B1 | GLP-1 ANALOGUES AND DERIVATIVES | NOVO NORDISK AS (DK) | 2017-03-01 | — | — | EP | disclosed |
| US-20170051034-A1 | Novel Glucagon Analogues | NOVO NORDISK AS (DK) | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10588936-B2 | Modulators of complement activity | C3AR1, C1QBP, C5AR1 | GLP1R 575/4885NOD1 1517/4885FOLH1 801/4885 |
| US-20240209028-A1 | CNP COMPOUNDS | NPPA, NPR1, NPR3 | GLP1R 19/4885NOD1 622/4885FOLH1 562/4885 |
| US-20170137468-A1 | MODULATION OF COMPLEMENT ACTIVITY | C5, C3AR1, CFH | GLP1R 3416/4885NOD1 1423/4885FOLH1 944/4885 |
| US-20190016768-A1 | EGF(A) ANALOGUES WITH FATTY ACID SUBSTITUENTS | EGFR, LDLR, FFAR2 | GLP1R 39/4885NOD1 4794/4885FOLH1 1459/4885 |
| US-20190307835-A1 | MODULATORS OF COMPLEMENT ACTIVITY | C3AR1, C1QBP, C5AR1 | GLP1R 575/4885NOD1 1517/4885FOLH1 801/4885 |
| US-11130794-B2 | Bifunctional compounds | GLP1R, PCSK9, PCSK7 | GLP1R 1/4885NOD1 743/4885FOLH1 191/4885 |
| US-10822385-B2 | EGF(A) analogues with fatty acid substituents | EGFR, LDLR, FFAR2 | GLP1R 39/4885NOD1 4794/4885FOLH1 1459/4885 |
| US-20200407409-A1 | EGF(A) ANALOGUES WITH FATTY ACID SUBSTITUENTS | EGFR, LDLR, FFAR2 | GLP1R 39/4885NOD1 4794/4885FOLH1 1459/4885 |
| US-20200231645-A1 | Bifunctional compounds | GLP1R, PCSK9, PCSK7 | GLP1R 1/4885NOD1 743/4885FOLH1 191/4885 |
| US-20170051034-A1 | Novel Glucagon Analogues | GLP1R, GIPR, IAPP | GLP1R 1/4885NOD1 1856/4885FOLH1 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.